Twin Lakes Capital Management, LLC Protagonist Therapeutics, Inc Transaction History

Twin Lakes Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $984,142 - $3.56 Million	-139,397 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$23.34 - $36.08 $19,068 - $29,477	817 Added 0.59%	139,397 $3.3 Million
Q4 2021 Feb 07, 2022	SELL	$17.63 - $37.1 $12,464 - $26,229	-707 Reduced 0.51%	138,580 $4.74 Million
Q3 2021 Nov 01, 2021	SELL	$12.95 - $49.69 $53,781 - $206,362	-4,153 Reduced 2.9%	139,287 $2.47 Million
Q2 2021 Aug 06, 2021	BUY	$25.57 - $44.88 $14,216 - $24,953	556 Added 0.39%	143,440 $6.44 Million
Q1 2021 May 18, 2021	BUY	$19.02 - $31.15 $7,627 - $12,491	401 Added 0.28%	142,884 $3.7 Million
Q4 2020 Feb 26, 2021	BUY	$18.49 - $25.13 $2.63 Million - $3.58 Million	142,483 New	142,483 $2.87 Million

247

56.4M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.92B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Twin Lakes Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Twin Lakes Capital Management, LLC with notifications on news.